Trial record 1 of 1 for:
IDE196-002
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05987332 |
|
Recruitment Status :
Recruiting
First Posted : August 14, 2023
Last Update Posted : May 9, 2024
|
Sponsor:
IDEAYA Biosciences
Information provided by (Responsible Party):
IDEAYA Biosciences
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 15, 2027 |
| Estimated Study Completion Date : | January 15, 2028 |